IQVIA Holdings Inc. (NYSE:IQV) Shares Bought by Commerce Bank

Commerce Bank increased its position in shares of IQVIA Holdings Inc. (NYSE:IQV) by 1.6% in the 4th quarter, HoldingsChannel reports. The firm owned 71,898 shares of the medical research company’s stock after purchasing an additional 1,167 shares during the period. Commerce Bank’s holdings in IQVIA were worth $14,129,000 as of its most recent filing with the Securities & Exchange Commission.

Other hedge funds have also recently added to or reduced their stakes in the company. Smith Group Asset Management LLC purchased a new position in shares of IQVIA during the 4th quarter worth approximately $1,616,000. Nordea Investment Management AB raised its position in IQVIA by 47.4% in the fourth quarter. Nordea Investment Management AB now owns 1,405,281 shares of the medical research company’s stock worth $277,908,000 after acquiring an additional 452,029 shares in the last quarter. Hickory Asset Management Inc. acquired a new position in shares of IQVIA during the 4th quarter worth $941,000. Fifth Third Bancorp lifted its stake in shares of IQVIA by 13.0% in the fourth quarter. Fifth Third Bancorp now owns 13,179 shares of the medical research company’s stock valued at $2,590,000 after purchasing an additional 1,521 shares during the period. Finally, Graphene Investments SAS increased its holdings in IQVIA by 22.0% in the fourth quarter. Graphene Investments SAS now owns 15,000 shares of the medical research company’s stock valued at $2,948,000 after buying an additional 2,700 shares in the last quarter. Institutional investors and hedge funds own 89.62% of the company’s stock.

IQVIA Stock Performance

NYSE IQV opened at $143.66 on Friday. IQVIA Holdings Inc. has a 1-year low of $135.97 and a 1-year high of $252.88. The business’s 50-day simple moving average is $176.42 and its 200-day simple moving average is $196.86. The company has a debt-to-equity ratio of 2.12, a current ratio of 0.84 and a quick ratio of 0.84. The firm has a market capitalization of $25.33 billion, a P/E ratio of 19.15, a P/E/G ratio of 1.99 and a beta of 1.46.

IQVIA (NYSE:IQV) last posted its earnings results on Thursday, February 6th. The medical research company reported $2.90 earnings per share for the quarter, missing the consensus estimate of $3.11 by ($0.21). IQVIA had a net margin of 8.91% and a return on equity of 28.81%. Equities analysts predict that IQVIA Holdings Inc. will post 10.84 EPS for the current year.

Analyst Upgrades and Downgrades

Several equities analysts recently issued reports on the company. Citigroup reduced their price objective on IQVIA from $225.00 to $210.00 and set a “neutral” rating for the company in a report on Tuesday, March 4th. Robert W. Baird lowered their price objective on shares of IQVIA from $212.00 to $210.00 and set a “neutral” rating on the stock in a research note on Tuesday, January 21st. Mizuho reduced their price target on shares of IQVIA from $242.00 to $210.00 and set an “outperform” rating on the stock in a report on Wednesday, April 9th. Stifel Nicolaus lowered their target price on IQVIA from $273.00 to $261.00 and set a “buy” rating on the stock in a report on Friday, February 7th. Finally, Morgan Stanley upped their price objective on IQVIA from $245.00 to $250.00 and gave the company an “overweight” rating in a research report on Tuesday, February 11th. Six investment analysts have rated the stock with a hold rating, sixteen have assigned a buy rating and one has assigned a strong buy rating to the company’s stock. Based on data from MarketBeat.com, IQVIA presently has an average rating of “Moderate Buy” and an average price target of $241.50.

About IQVIA

IQVIA Holdings Inc engages in the provision of advanced analytics, technology solutions, and clinical research services to the life sciences industry in the Americas, Europe, Africa, and the Asia-Pacific. It operates through three segments: Technology & Analytics Solutions, Research & Development Solutions, and Contract Sales & Medical Solutions.